نبذة مختصرة : Funding Information: The authors would like to thank our colleagues from the Translational Research Unit and the Flow cytometry Core facility of OUS for providing technical assistance. We are grateful to Gibco and Life Technologies AS for supplying CTS™ Dynabeads™ CD3/CD28 and Drs. Mengyu Wang and Hanne B. Scholz (Oslo University Hospital) for providing the mesenchymal stem cells. We thank Prof. Michael Nishimura (Loyola University Chicago Stritch School of Medicine, USA) for sharing the truncated CD34 sequence. This study was supported by the Norwegian Research Council (Grant numbers: 284983 and 316407 to S.W. and 326811 to E.M.I), the Norwegian Health Region South East (Grant numbers: 2020601, 2018579, 2016006 and 2019062 to S.W. and 2019004 to E.M.I.) and S.J. is supported by the Norwegian Research Council under the frame of the Era-Net EURONANOMED-3 European Research project “NAN-4-TUM”. We thank Nova Southeastern University Center for Collaborative Research Core Facilities personnel Dr. Robin Krueger, Solly-Ann Barton-Case and Dr. Bojie Dai for their support in generation of RNAseq data. A.-M.G. was supported by the Swedish Society for Medical Research (SSMF). Research in P.M.’s Laboratory was funded by “la Caixa” Foundation Validate Program, ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resilencia), and core support from CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa, the CaixaImpulse Grant CI21-00189, which has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2021 research and innovation program. C.P. is supported by a PFIS fellowship from Instituto de Salud Carlos III (ISCIII) (FI21/00161). Figures 3 a, 3 e, 4a , ad Supplementary Fig. 4a were prepared using BioRender.com. Funding Information: The authors would like to thank our colleagues from the Translational Research Unit and the Flow cytometry Core facility of ...
Relation: Nature Communications; 14(1); http://www.scopus.com/inward/record.url?scp=85161398175&partnerID=8YFLogxK; Mensali , N , Köksal , H , Joaquina , S , Wernhoff , P , Casey , N P , Romecin , P , Panisello , C , Rodriguez , R , Vimeux , L , Juzeniene , A , Myhre , M R , Fåne , A , Ramírez , C C , Maggadottir , S M , Duru , A D , Georgoudaki , A M , Grad , I , Maturana , A D , Gaudernack , G , Kvalheim , G , Carcaboso , A M , de Alava , E , Donnadieu , E , Bruland , Ø S , Menendez , P , Inderberg , E M & Wälchli , S 2023 , ' ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma ' , Nature Communications , vol. 14 , no. 1 , 3375 , pp. 3375 . https://doi.org/10.1038/s41467-023-39097-x; 155771172; 7b786bae-f7a3-4819-96c7-71f819f1c9c5; 85161398175; unpaywall: 10.1038/s41467-023-39097-x; https://hdl.handle.net/20.500.11815/4388
No Comments.